Nicholas James and James N'Dow discuss the findings and objectives of the Lancet Prostate Cancer Commission. Professor James outlines the initiative's global scope and multidisciplinary approach to tackling prostate cancer, emphasizing the diverse representation and expertise spanning various regions and specialties. The discussion highlights the comprehensive analysis undertaken over three years, culminating in a document that offers innovative recommendations for future strategies. Professor N'Dow, leading the diagnostic and screening section, addresses the complexities of early diagnosis and the potential for risk-adapted detection to balance the scales between overdiagnosis in high-income regions and late-stage presentations in lower-income countries. Both experts stress the imminent surge in prostate cancer cases, particularly in sub-Saharan Africa, underscoring the need for scalable diagnostic systems, education, and a proactive approach to healthcare disparities.

Biographies:

Professor Nicholas James, MBBS, FRCP, FRCR, Ph.D., Professor of Clinical Oncology at the Institute of Cancer Research at Royal Marsden Hospital, London

James N’Dow, Professor, Chair in Surgery (Clin), Director of the Academic Urology Unit, University of Aberdeen

Alicia Morgans, MD, MPH, Genitourinary Medical Oncologist, Medical Director of Survivorship Program at Dana-Farber Cancer Institute, Boston, MA